A prospective, single-centre, single-arm, open label study of the long term use of a gonadotropin releasing hormone agonist (Triptorelin SR, [amount hidden]) in combination with Tibolone add-back therapy in the management of chronic cyclical pelvic pain

What Was Tested

Researchers studied Triptorelin in the context of chronic pain: fibromyalgia & crps in this clinical trial publication.

Chronic cyclic pelvic pain (CCPP) affects women's quality of life and pituitary downregulation is often used for symptomatic relief.

Who Took Part

The study group was 27 patients.

By PubMed's age tags, the people studied were adults, women only.

Outcomes measures were the safety of treatment assessed by clinical examination, haematological markers, liver and renal function tests and bone mineral density (BMD) at 12, 18 and 24 months as well as at 6 months post-treatment.

How the Study Was Run

Pain and health-related quality of life (HR-QoL) assessed using the endometriosis health profile (EHP-30) and chronic pain grade (CPG) questionnaires.

What Was Measured

Topics PubMed links to this paper include Bone Density, Chronic Pain, Norpregnenes, Pain Measurement, Pelvic Pain, Quality of Life and Triptorelin Pamoate.

Author keywords: Add back therapy, Chronic cyclic pelvic pain, Endometriosis and GnRH.

What This Means in Plain Language

This is a clinical trial of Triptorelin in 27 patients in people with chronic pain: fibromyalgia & crps.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2020 (Reproductive biology and endocrinology : RB&E), a journal based in England.

More context: the Triptorelin compound page, Chronic pain: fibromyalgia & CRPS research.